No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
REGN240705C1080000
- 2.00
- -0.67-25.09%
15min DelayClose Jul 1 16:00 ET
2.35High2.00Low
2.35Open2.67Pre Close2 Volume4 Open Interest1080.00Strike Price435.00Turnover20.91%IV2.36%PremiumJul 5, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry2.00Extrinsic Value100Contract SizeAmericanOptions Type0.1672Delta0.0110Gamma528.51Leverage Ratio-0.7549Theta0.0184Rho88.38Eff Leverage0.2716Vega
Intraday
- 5D
- Daily
News
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 1.19 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Regeneron Pharmaceuticals(REGN.US)$ Officer MARION E MCCOURT intends to sell 1,137 shares of its common stock on Jul 1, with a total market value of approximately $1.19
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
CHMP Recommends Regeneron Lymphoma Antibody Drug for Conditional Approval
Regeneron's Odronextamab Receives Opinion From EMA for Lymphoma Treatment
Express News | Odronextamab Recommended for EU Approval by the Chmp to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
Comments
$Regeneron Pharmaceuticals(REGN.US$
🔔 FDA Approves Kevzara® (sarilumab)
» for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) 🦴
» sBLA approval in patients with pJIA weighing ≥ 63kg
» adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis & polymyalgia rheumatica
🔔 FDA Approves Kevzara® (sarilumab)
» for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) 🦴
» sBLA approval in patients with pJIA weighing ≥ 63kg
» adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis & polymyalgia rheumatica
3
1
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
9
1
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
16
Nvidia announced its sixth stock split, with shares set to trade at one-tenth their current price starting June 10, 2024. Before the Q1 2024 earnings call on May 22, when the split was revealed, NVDA closed at $949.50. Since then, the stock has surged past the $1,150 mark, reaching all-time highs. To be eligible for the split shares, investors must own the stock by the market close at 4 pm ET on June 6, 2024. Nvidia's last 4-for-1 split i...
+2
329
76
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
75
2
Read more
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!